PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo

PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo

Abstract H3K27-altered Diffuse Midline Glioma (DMG) is a universally fatal paediatric brainstem tumour. The prevalent driver mutation H3K27M creates a unique epigenetic landscape that may also establish therapeutic vulnerabilities to epigenetic inhibitors. However, while HDAC, EZH2 and BET inhibitor...

Full description

Bibliographic Details
Main Authors: Elizabeth J. Brown, Leire Balaguer-Lluna, Adam P. Cribbs, Martin Philpott, Leticia Campo, Molly Browne, Jong Fu Wong, Udo Oppermann, Ángel M. Carcaboso, Alex N. Bullock, Gillian Farnie
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-48652-x

Internet

https://doi.org/10.1038/s41598-023-48652-x

Similar Items